Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 5/20 | 0.52 |
| ▸ | CTSL | P07711 | 3/20 | 0.51 |
| ▸ | CTSB | P07858 | 2/20 | 0.51 |
| ▸ | CTSS | P25774 | 2/20 | 0.51 |
| ▸ | CASP1 | P29466 | 6/20 | 0.50 |
| ▸ | KLK7 | P49862 | 1/20 | 0.50 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14680593 | 0.91 | SYK (0.56) | SYKCTSKCTSLCTSBCTSS | |
| SCHEMBL3478705 | 0.90 | KLK5 (0.60) | SYKCTSKCTSLCTSBCTSS | |
| SCHEMBL15559104 | 0.90 | KLK5 (0.60) | SYKCTSKCTSLCTSBCTSS | |
| SCHEMBL11598914 | 0.90 | KLK5 (0.60) | SYKCTSKCTSLCTSBCTSS | |
| SCHEMBL1143898 | 0.90 | PPARA (0.57) | SYKCTSKCTSLCTSBCTSS | |
| SCHEMBL2775895 | 0.90 | PPARA (0.57) | SYKCTSKCTSLCTSBCTSS | |
| SCHEMBL29398102 | 0.90 | SYK (0.57) | SYKCTSKCTSLCTSBCTSS | |
| SCHEMBL478289 | 0.90 | PPARA (0.57) | SYKCTSKCTSLCTSBCTSS | |
| Hydrochloric Acid SCHEMBL11598965 | 0.89 | KLK5 (0.59) | SYKCTSKCTSLCTSBCTSS | |
| SCHEMBL4256075 | 0.89 | KYNU (0.56) | SYKCTSKCTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392280-A4 | ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF | WARNER LAMBERT CO (US) | 2005-11-30 | — | — | EP | disclosed |
| US-6875765-B2 | Arylsulfonamide ethers, and methods of use thereof | WARNER-LAMBERT COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
| EP-1392280-A2 | ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF | Abbott GmbH & Co. KG (DE) | 2004-03-03 | — | — | EP | disclosed |
| US-20030096826-A1 | Arylsulfonamide ethers, and methods of use thereof | WARNER-LAMBERT COMPANY | 2003-05-22 | — | — | US | disclosed |
| WO-2002089749-A2 | ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF | ABBOTT GMBH & CO.KG (DE) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096826-A1 | Arylsulfonamide ethers, and methods of use thereof | CASP1, IRAK1, STS | SYK 1265/4885CTSK 172/4885CTSL 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.